Fapon Showcases Innovative Diagnostic and Biopharma Solutions

Fapon Biotech (Guangdong, China) is presenting its latest innovations in in-vitro diagnostic and biopharma solutions at the 2023 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo.

At AACC 2023, Fapon is introducing its latest chemiluminescence immunoassay (CLIA) system, the Shine i8000/9000. This ultra-high throughput, fully automated analyzer delivers initial results within 10 minutes at a rate of 900 tests per hour. The system's high throughput per footprint, delivering 377 tests/hour/m2, makes it an ideal choice for labs seeking to boost their testing capacity and efficiency. The launch of the Shine i8000/9000 further expands the company's extensive portfolio of high, medium, and low-throughput chemiluminescence analyzers. Fapon continues to integrate its one-stop solution on CLIA raw materials, reagents, and open instruments services to further innovate clinical diagnostic solutions for its IVD partners.

With a 22-year background in IVD raw materials, Fapon is presenting its extensive core IVD raw materials solutions for immunoassay and PCR & LAMP. At AACC 2023, the company is spotlighting its high-quality respiratory raw materials designed to expedite the development of rapid tests for SARS-CoV-2, Influenza A/B and RSV antigen-based multi-analyte tests. These materials offer authoritative panel validation, superior sensitivity, and affordable, high-quality supply. Also, the company is introducing its qPCR lyophilized master mix, featuring high activity before and after lyophilization, robust stability, quick solubilized cakes/beads, and customizable solutions and lyophilization service.

Fapon is also highlighting its groundbreaking solution for drug discovery and development. Fapon Biopharma, its subsidiary, has developed a fully-integrated platform for novel biological products, comprising programs from the discovery to clinical research stages. The company's antibody platform specializes in developing and manufacturing innovative antibodies and fusion proteins. Fapon excels in antibody discovery, bispecific antibodies, antibody-cytokine fusion proteins, and PROTiNB. The development of FP002, a superior anti-tumor efficacy and high-reliability anti-CD47 drug, demonstrates Fapon's comprehensive capabilities from early discovery, CMC, preclinical studies to clinical registration. The cell therapy platform focuses on universal and next-generation CAR-T cell therapies for solid tumors, with their flagship product FC001 targeting CD19.

As the global leader in circular RNA technology, Fapon continues to address the technical bottlenecks of circRNA industrialization and demonstrate its competitive advantage in the industry through various cooperative models. At AACC 2023, Fapon is also delivering an interactive lecture titled "Bioanalytical Performance of Novel Protein-free Blockers & Heterophilic Antibody Interference Blockers for the IVD Industry & Clinical Diagnostics," offering insights into the latest advancements in IVD blockers.

"We are thrilled to be showcasing our latest solutions and offerings at the 2023 AACC Expo," said Jielun ZHU, CFO & CIO of Fapon. "Fapon is committed in becoming a global leading provider of fundamental technological solutions for diagnosis and biotherapy. We aim to establish a global open ecosystem with our partners to develop cutting-edge diagnostic and biopharma solutions that can address diverse needs in healthcare."

Related Links:
Fapon Biotech